At a glance
ClinicalIndex Comparison RecordPhase 2Active· 106 enrolled
Drug / intervention
Belantamab mafodotin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 3 - Belantamab Mafodotin and Nirogacestat in Combination
In Brief
A Phase 2 clinical trial evaluating Belantamab mafodotin and Nirogacestat for Multiple Myeloma. Active but no longer recruiting, targeting 106 participants across 29 sites in 13 countries.
Detailed Summary
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesAustralia, Canada, France, Germany, Greece, Netherlands, Norway, Poland, Russia, South Korea, Spain, Sweden, United States
Collaborators--
Timeline
Phase 2Active
2021202220232024202520262027
Enrollment StartJun 2020
Primary CompletionApr 2025
First PostedJul 2025
TodayJul 2026
Study CompletionMar 2027
First PostedJul 25, 2025
Enrollment StartJun 8, 2020
Primary CompletionApr 17, 2025
Study CompletionMar 11, 2027
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 11 months ago
Interventions
Belantamab mafodotindrug
Belantamab mafodotin will be administered.
Nirogacestatdrug
Nirogacestat will be administered.